iBET was present at the Integrated Continuous Biomanufacturing III Conference

Continuous bioprocessing has the inherent advantage of higher productivity which can facilitate implementation of small process trains, resulting in cost-effective, lean, and agile manufacturing facilities.  Impressive technological advances to enable continuous bioprocessing have been made in the recent past and have been discussed at Integrated Continuous Biomanufacturing (ICB) I (2013) and II (2015) conferences.  The range of topics that were discussed illustrates the active and enthusiastic engagement of biopharmaceutical industry, academia, and regulatory authorities.

ICB III (2017) succeeded to build on the strong momentum generated at the previous two conferences in the series.  The agenda included progress on the state-of-the-art technologies and emerging trends in continuous upstream, downstream, and drug product unit operations.  Case studies for the implementation of continuous platforms were discussed, spanning scale-down mimics and control strategies through to end-to-end continuous processes and facility designs.

The ICB conference brought together leading scientists and engineers from academic, industry and regulatory authorities who are actively engaged in integrated continuous bioprocessing. 

The meeting was held at Hotel Cascais Miragem from 17 to 21 September and was co-chaired by Paula Alves (iBET, Portugal), Suzanne Farid, (University College London, UK), Chetan Goudar (Amgen, USA) and Veena Warikoo (Axcella Health, Inc., USA).

iBET participation involved the chairing of the Continuous Purification and Drug Product Sequences session by Manuel Carrondo, two oral presentations (Ricardo Silva and Bernardo Abecasis).

After the meeting, participants were invited to visit iBET where they had the opportunity to learn more on our activities, visit our laboratories, Pilot Plant and Analytical Services Unit.